Decibel Therapeutics Inc. (DBTX)
$4.91
$0.00 (0.00%)As on 04-Oct-2023 09:30EDT
Market cap
$123 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-47 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.5
-
Face value
--
-
Shares outstanding
25,126,900
5 Years Aggregate
CFO
$-218.20 Mln
EBITDA
$-227.93 Mln
Net Profit
$-229.89 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Decibel Therapeutics (DBTX)
| 139.5 | -3.9 | 30.6 | 40.3 | -- | -- | -- |
|
BSE Sensex*
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
Company
|
2022
|
|---|---|
|
Decibel Therapeutics (DBTX)
| -55.9 |
|
BSE Sensex
| 4.4 |
|
BSE Sensex
| 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Decibel Therapeutics (DBTX)
|
4.9 | 123.4 | 0.0 | -63.4 | -- | -93.8 | -- | 0.7 |
| 85.0 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 73.3 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.3 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 108.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 370.9 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 545.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.5 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 148.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Decibel Therapeutics (DBTX)
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene... Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc. Read more
-
Pres, CEO & Director
Dr. Laurence E. Reid Ph.D.
-
Pres, CEO & Director
Dr. Laurence E. Reid Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Decibel Therapeutics (DBTX)
What is the current share price of Decibel Therapeutics Inc (DBTX) Today?
The share price of Decibel Therapeutics Inc (DBTX) is $4.91 (NASDAQ) as of 04-Oct-2023 09:30 EDT. Decibel Therapeutics Inc (DBTX) has given a return of 40.29% in the last 1 years.
What is the current PB & PE ratio of Decibel Therapeutics Inc (DBTX)?
Since, TTM earnings of Decibel Therapeutics Inc (DBTX) is negative, P/E ratio is not available.
The P/B ratio of Decibel Therapeutics Inc (DBTX) is 0.67 times as on 04-Oct-2023, a 87 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.81 |
0.63 |
2021 |
-2.23 |
0.82 |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Decibel Therapeutics Inc (DBTX)?
The 52-week high and low of Decibel Therapeutics Inc (DBTX) are Rs -- and Rs -- as of 03-Sep-2026.
What is the market cap of Decibel Therapeutics Inc (DBTX)?
Decibel Therapeutics Inc (DBTX) has a market capitalisation of $ 123 Mln as on 04-Oct-2023. As per SEBI classification, it is a company.
Should I invest in Decibel Therapeutics Inc (DBTX)?
Before investing in Decibel Therapeutics Inc (DBTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.